ArticleCell reports2019
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- The role of glutamate receptors in the regulation of the tumor microenvironment.Frontiers in immunology · 2023Pooled it
- A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer.Science advances · 2026Article
- Potential medical applicability of N-β-Ala and N-His dipeptidomimetics against breast cancer: short in vitro and in silico screening.Scientific reports · 2026Article
- Aberrant amino acid-sensing promotes immunotherapy resistance via the inflammatory cytokine-ZBTB5-mTORC1 axis.Nature cell biology · 2026Article
- Targeting metabolism to combat anticancer and antibacterial drug resistance.Trends in pharmacological sciences · 2026Review
- Amino acid metabolic regulatory network in tumor immune escape: mechanistic exploration and intervention directions.Frontiers in immunology · 2026Review
- CD44 and SLC1A2 are commonly regulated but do not form a fusion transcript in ER+ breast cancer.Molecular and cellular biochemistry · 2025Article
- Amino acid metabolism in breast cancer: pathogenic drivers and therapeutic opportunities.Protein & cell · 2025Review
- Emerging Insights into the Relationship Between Amino Acid Metabolism and Diabetic Cardiomyopathy.Biomolecules · 2025Review
- Article
- MicroRNAs and their role in breast cancer metabolism (Review).International journal of oncology · 2025Review
- Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype.Current issues in molecular biology · 2024Review
- A metabolic reprogramming-related gene signature correlates with prognosis and proliferation of BLCA.Discover oncology · 2024Article
- DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma.Acta neuropathologica communications · 2024Article
- Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- A gold-based inhibitor of oxidative phosphorylation is effective against triple negative breast cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer.Cell death & disease · 2023Article
- The Role of Amino Acids in the Diagnosis, Risk Assessment, and Treatment of Breast Cancer: A Review.Current issues in molecular biology · 2023Review
- Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer.Journal of the Endocrine Society · 2023Article
- Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.Nature communications · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 4 countries.
Marina BacciDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Nicla LoritoDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Luigi IppolitoDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Matteo RamazzottiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Simone LutiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Simone RomagnoliDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Matteo ParriDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Francesca BianchiniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Federica CappellessoVIB Center for Cancer Biology, Department of Oncology, University of Leuven, Leuven 3000, Belgium.
Federico VirgaVIB Center for Cancer Biology, Department of Oncology, University of Leuven, Leuven 3000, Belgium; Molecular Biotechnology Center (MBC), Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin 10126, Italy.
Qiong GaoThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Bruno M SimõesBreast Cancer Now Research Unit, Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4GJ, UK.
Elisabetta MarangoniInstitut Curie, PSL Research University, Translational Research Department, Paris 75248, France.
Lesley-Ann MartinThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Giuseppina ComitoDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Manuela FerracinDepartment of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna 40126, Italy.
Elisa GiannoniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Massimiliano MazzoneVIB Center for Cancer Biology, Department of Oncology, University of Leuven, Leuven 3000, Belgium.
Paola ChiarugiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy.
Andrea MorandiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy. Electronic address: andrea.morandi@unifi.it.
University of Florence · ITVIB-KU Leuven Center for Cancer Biology · BEInstitute of Cancer Research · GBBreast Cancer Now · GBUniversité Paris Sciences et Lettres · FRUniversity of Bologna · IT
Funding
European Research Council 773208
Abstract
Endocrine therapy (ET) is the standard of care for estrogen receptor-positive (ER
Indexed as
Amino Acid Transport SystemsAmino Acid Transport Systems, NeutralAnimalsAspartic AcidBreast NeoplasmsCell Line, TumorCell SurvivalDrug Resistance, NeoplasmEstrogen Receptor alphaExcitatory Amino Acid Transporter 2FemaleGas Chromatography-Mass SpectrometryGATA2 Transcription FactorGene Expression Regulation, NeoplasticGlutamic AcidHumansAmino Acid Transport SystemsAmino Acid Transport Systems, NeutralAspartic AcidEstrogen Receptor alphaExcitatory Amino Acid Transporter 2GATA2 protein, humanGATA2 Transcription FactorGlutamic AcidMicroRNAsMIRN23b microRNA, humanSLC1A2 protein, humanSLC6A14 protein, humanamino acid transportersaspartateendocrine therapyestrogen receptorglutamatemetabolic reprogrammingmiRNAresistanceSLCs
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.